DOCSLIB.ORG

Quetiapine-Associated Tardive Dyskinesia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quetiapine-Associated Tardive Dyskinesia 74 Taiwanese J Psychiatry Vol. 22 No. 1 2008 Quetiapine-associated Tardive Dyskinesia Hsing-Kang Chen, M.D.1, Chin-Bin Yeh, M.D.1,2, Wei-Wen Lin, M.D, Ph.D.1,2,3 Objective: To report a case of tardive dyskinesia in a patient treated with quetiapine. Case report: A 51-year-old male had been treated with antipsychitics for 3 years, including clothiapine 40 mg/d, risperidone 2-4 mg/d, and zotepine 150 mg/d, individually. He was switched from zotepine to quetiapine 400 mg/d due to parkinsonism, which subsided 1 week after the change, however, the TD symptoms were subsequently noted 5 months later. These symptoms improved significantly after discontinuation of the quetiapine, but worsened after the quetiapine (400 mg/d) was again prescribed during admission to another hospital. In the beginning of his latest hospitalization, all medications were discontinued because the patient’s manic symptoms had been in full remission for at least 10 months. He was discharged 3 weeks after hospitalization with significant improvement of the TD symptoms. Conclusion: This single case report suggests that quetiapine might be associated with occurrence of TD symptoms although the frequency is presumably much rarer than that of conventional antipsychotics. Key words: antipsychotics, tardive dyskinesia, quetiapine, bipolar disorder (Taiwanese J Psychiatry 2008;22:74-8) observed. Herein, we report the case of a 51-year- Introduction old male with reemerging TD associated with quetiapine treatment. Second-generation antipsychotics (SGAs) are reportedly associated with much lower incidence of Case Report TD than conventional analogs. Of these, quetiapine has a low striatal D2 receptor-binding profile, with A 51-year-old married Taiwanese male the rapid release from D2 receptors [1] making it presented to our psychiatric ward with complaints less likely to cause extrapyramidal symptoms of involuntary oral and facial movements that had (EPS) or tardive dyskenisia (TD). Although there persisted for about 3 weeks. He had experienced his are many case reports of associated SGA-induced first manic episode at the age of 38 years and was TD, to date, we only found three published articles subsequently admitted to our hospital. He involving eight cases where development or commenced treatment with lithium 900 mg/d, worsening of TD during quetiapine treatment was clothiapine 40 mg/d and clonazepam 4 mg/d in 1Department of Psychiatry, Tri-Service General Hospital 2Department of Psychiatry, National Defense Medical Center 3Peaceful Mind Clinic Received: January 31, 2007; revised: October 30, 2007; accepted: November 12, 2007 Address correspondence to: Dr Wei-Wen Lin, Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Gung Road, Taipei 114, Taiwan Chen HK, Yeh CB, Lin WW 75 April 2001 (age 49 years). The clothiapine dosage mg/d, clonazepam 2 mg/d, midazolam 7.5 mg/d was raised to 120 mg/d and parkinsonism, and trihexiphenidyl 6 mg/d. including drooling and slurred speech, was noted His personal history was unremarkable except during this treatment, with the parkinsonism for the fact that he was a twin. He denied history of symptoms subsiding soon after discontinuation. He any movement disorder before taking psychotropic was then switched to sodium valproate 600 mg/d agents. He had also suffered herniation of and risperidone 2-6 mg/d in November 2001 due to intervertebral discs at C3/4, C5/6 and C6/7, which exacerbation of manic symptoms. Parkinsonism had been treated with radiculopathy and was developed again under risperidone 6 mg/d, conservative follow-up treatment for the preceding disappearing after its withdrawal and the addition 5 years. He also had a history of alcohol of an anticholinergic agent. In April 2003, he dependence starting at the age of 23 years but had suffered a manic relapse and sodium valproate abstained from April 2003. His twin brother also 1500 mg/d, clonazepam 4 mg/d and zotepine 150 had a similar history of alcohol dependence without mg/d were prescribed. Parkinsonism reemerged abstaining and bipolar I disorder. The patient’s and the zotepine was switched to quetiapine 400 early development and history were unremarkable. mg/day via cross titration. Biperiden 4 mg/d was The patient was the youngest of the four children in also added and the parkinsonism improved 1 week his family. later. He was discharged without obvious EPS after Initial examination revealed a thin, adult male 3 weeks of hospitalization, and has been regularly of aged appearance relative to his chronological followed up at our outpatient clinic. age. He appeared anxious, with oro-facial Five months later, he experienced repetitive dyskinesia, repetitive and involuntary mouth and involuntary mouth opening and facial opening, and facial grimacing without trunk or limb grimacing. These movement problems persisted involvement. His vital signs were within normal despite decreasing the quetiapine dose to 200 mg/d range. No throat congestion or other signs of upper and the addition of trihexiphenidyl 4-6 mg/d. airway infection were noted. Mental status was Quetiapine was discontinued after 8 weeks, and the otherwise normal, with cranial nerve examination TD symptoms markedly improved 12 weeks later. also normal. Neurological examination revealed The trihexiphenidyl was stopped soon after the TD tingling sensations in the bilateral thumbs, and the improved. He visited another hospital for his neck index and ring fingers. pain and was referred to their psychiatric clinic for After admission, all medications were the residual TD symptoms where quetiapine 400 discontinued under the condition that full remission mg/d was prescribed again. The TD symptoms of his manic symptoms was achieved. His baseline promptly worsened and persisted for 3 weeks prior Abnormal Involuntary Movement Scale (AIMS) to his latest admission at our hospital. He then score was 21. One week after admission, we visited our outpatient clinic where we discontinued prescribed trihexyphenidyl 4 mg/d for 10 days, the quetiapine for about 1 week and he was withdrawing it because of poor response. During admitted to our ward for further evaluation and this period, however, the TD symptoms did not management in April 2004 due to symptom worsen. Finally, he was maintained on clonazepam persistence. Immediately prior to this admission, 4 mg/d and lormetazepam 1 mg/d. The results of his medications had been sodium valproate 600 the laboratory tests and brain magnetic resonance 76 Quetiapine and Tardive Dyskinesia imaging ordered by the neurologist were all free of movement disorders for at least 5 months unremarkable. The patient was discharged after 4 before developing TD, with the symptoms only weeks of hospitalization with an AIMS score of 7. emerging with the quetiapine treatment. His TD symptoms partially improved after tapering of the Discussion quetiapine, subsequently reemerging after further administration of the drug by another psychiatrist at Eight cases of quetiapine-associated TD have a different hospital. Thus, there is a temporal been reported, with five developing neuroleptic- relationship between the quetiapine administration induced EPS or TD prior to quetiapine and occurrence of the TD. It appears reasonable to administration (Table 1). Just three of the remaining assume, therefore, that the TD symptoms were cases had previously been free from EPS and TD. associated with the quetiapine administration. This demonstrates that, in most patients, these Trihexiphenidyl, an anticholinergic agent, dysfunctions are more likely to have been induced may exacerbate TD symptoms [2]; however, the by previous neuroleptic exposure than by link between the use of the anticholinergic and the quetiapine. Although our patient had experienced emergence of TD may be only an epiphenomena as parkinsonism after exposure to clothiapine, the subgroup of patients who develop EPS are zotepine and risperidone prior to the quetiapine thought to be more likely to receive anticho- administration, the symptoms disappeared soon linergics and also to develop TD [3]. In our case, after the withdrawal of clothiapine or addition of biperiden 2-6 mg/d was administered after the anticholinergic agents while discontinuing patient had developed TD for 2 months and risperidone or zotepine. In addition, he had been restarted at 4 mg/d for 10 days after a week’s Table 1. Case reports of quetiapine-associated tardive dyskinesia Duration of Diagnosis Quetiapine dose Previous Case no.; author Age/Sex quetiapine (DSM-IV) (mg/d) EPS/TD therapy (weeks) Ghelber et al., [8] 44/F Schizophrenia 150 26 +/- 1 Ghaemi et al, [9] 25/M BPD, type I 125 6 -/- 2 Sharma et al., [10] 55/M MDD, recurrent 150 8 -/- 3 4 30/F BPD, type I 150 7 +/+ 5 48/F BPD, type II 225 12 +/- 6 54/F BPD, type I 300 10 +/+ 7 47/M BPD, type I 125 8 -/- 8 61/F MDD, recurrent 75 4 +/+ Chen et al, 2007, Jan 51 / M BPD, type I 400 24 +/- 9 Abbreviations: M = male; F = female; BPD = bipolar disorder; MDD = major depressive disorder. Chen HK, Yeh CB, Lin WW 77 hospitalization.; It was subsequently discontinued an explanation for low receptor occupancy and because of poor response, however. As the severity early clinical relapse upon withdrawal of clozapine of the TD symptoms did not change during this or quetiapine. Am J Psychiatry 1999; 156:876-84. period, it appears unlikely that the anticholinergic 2. Burnett GB, Prange AJ, Jr., Wilson IC, et al.: medication was responsible for the symptoms. We Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. an investigation of conclude, therefore, that the TD improvement was mechanism. Neuropsychobiology 1980; 6:109-20. not due to trihexyphenidyl administration but rather 3. American Psychiatric Association, Tardive that it was a consequence of the discontinuation of Dyskinesia: A Task Force Report of the American quetiapine. Psychiatric Association. Washington DC: Ameri- The risk factors for TD include long-term can Psychiatric Association, 1992.
Load more

Recommended publications
  • Tardive Dyskinesia
    Tardive Dyskinesia Tardive Dyskinesia Checklist The checklist below can be used to help determine if you or someone you know may have signs associated with tardive dyskinesia and other movement disorders. Movement Description Observed? Rhythmic shaking of hands, jaw, head, or feet Yes Tremor A very rhythmic shaking at 3-6 beats per second usually indicates extrapyramidal symptoms or side effects (EPSE) of parkinsonism, even No if only visible in the tongue, jaw, hands, or legs. Sustained abnormal posture of neck or trunk Yes Dystonia Involuntary extension of the back or rotation of the neck over weeks or months is common in tardive dystonia. No Restless pacing, leg bouncing, or posture shifting Yes Akathisia Repetitive movements accompanied by a strong feeling of restlessness may indicate a medication side effect of akathisia. No Repeated stereotyped movements of the tongue, jaw, or lips Yes Examples include chewing movements, tongue darting, or lip pursing. TD is not rhythmic (i.e., not tremor). These mouth and tongue movements No are the most frequent signs of tardive dyskinesia. Tardive Writhing, twisting, dancing movements Yes Dyskinesia of fingers or toes Repetitive finger and toe movements are common in individuals with No tardive dyskinesia (and may appear to be similar to akathisia). Rocking, jerking, flexing, or thrusting of trunk or hips Yes Stereotyped movements of the trunk, hips, or pelvis may reflect tardive dyskinesia. No There are many kinds of abnormal movements in individuals receiving psychiatric medications and not all are because of drugs. If you answered “yes” to one or more of the items above, an evaluation by a psychiatrist or neurologist skilled in movement disorders may be warranted to determine the type of disorder and best treatment options.
    [Show full text]
  • Tourette's Syndrome
    Tourette’s Syndrome CHRISTOPHER KENNEY, MD; SHENG-HAN KUO, MD; and JOOHI JIMENEZ-SHAHED, MD Baylor College of Medicine, Houston, Texas Tourette’s syndrome is a movement disorder most commonly seen in school-age children. The incidence peaks around preadolescence with one half of cases resolving in early adult- hood. Tourette’s syndrome is the most common cause of tics, which are involuntary or semi- voluntary, sudden, brief, intermittent, repetitive movements (motor tics) or sounds (phonic tics). It is often associated with psychiatric comorbidities, mainly attention-deficit/hyperac- tivity disorder and obsessive-compulsive disorder. Given its diverse presentation, Tourette’s syndrome can mimic many hyperkinetic disorders, making the diagnosis challenging at times. The etiology of this syndrome is thought to be related to basal ganglia dysfunction. Treatment can be behavioral, pharmacologic, or surgical, and is dictated by the most incapacitating symp- toms. Alpha2-adrenergic agonists are the first line of pharmacologic therapy, but dopamine- receptor–blocking drugs are required for multiple, complex tics. Dopamine-receptor–blocking drugs are associated with potential side effects including sedation, weight gain, acute dystonic reactions, and tardive dyskinesia. Appropriate diagnosis and treatment can substantially improve quality of life and psychosocial functioning in affected children. (Am Fam Physician. 2008;77(5):651-658, 659-660. Copyright © 2008 American Academy of Family Physicians.) ▲ Patient information: n 1885, Georges Gilles de la Tourette normal context or in inappropriate situa- A handout on Tourette’s described the major clinical features tions, thus calling attention to the person syndrome, written by the authors of this article, is of the syndrome that now carries his because of their exaggerated, forceful, and provided on p.
    [Show full text]
  • Tourette-Like Syndrome Following Low Dose Short-Term Neuroleptic Treatment Samarthji Lai and Esam Alansari
    LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES Tourette-like Syndrome Following Low Dose Short-term Neuroleptic Treatment Samarthji Lai and Esam AlAnsari ABSTRACT: A Tourette-like syndrome (TLS) may occur after long-term neuroleptic treatment. A review of 11 cases reported in the literature is given. We describe the onset of a TLS in a 13-year old boy with childhood schizophrenia after short term, low-dose treatment with thioridazine. The syndrome resolved 5 months after neuroleptic withdrawal. Subsequent exposure to neuroleptics (mainly perphenazine) induced a recurrence of motor tics and involuntary vocalizations which resolved on drug discontinuation. Awareness that neuroleptics may induce a TLS may lead to prompt recognition and avoidance of labelling the manifestations as symptoms of the underlying psychosis or attention-seeking behaviour. RESUME: Une syndrome analogue a ce de Gilles de la Tourette suivant le traitement prolonge par des neuroleptiques Un syndrome analogue au syndrome de Gilles de la Tourette peut survenir a la suite d'un traitement prolong^ par les neuroleptiques. Nous faisons une revue de 11 cas rapportes dans la litterature et nous decrivons le cas d'un jeune garcon de 13 ans souffrant de schizophrenic de I'enfance ayant presente un tel syndrome apres un traitement a la thioridazine a faible dose sur une courte periode de temps. Le syndrome s'est dissipe, 5 mois apres le retrait du neuroleptique. L'exposition subsequente a des neuroleptiques (surtout a la perphenazine), provoqua une reapparition des tics moteurs et des vocalisations involontaires qui disparurent a I'arret de la the>apie. La connaissance du fait que les neuroleptiques peuvent induire un syndrome analogue au Gilles de la Tourette peut conduire a un diagnostic rapide et eviter que ces manifestations soient etiquettees comme des symptomes de la psychose sous-jacente ou comme un comportement visant a attirer l'attention.
    [Show full text]
  • Clinical Study Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome
    Hindawi Publishing Corporation International Journal of Pediatrics Volume 2012, Article ID 843016, 11 pages doi:10.1155/2012/843016 Clinical Study Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome Elizabeth Berry-Kravis,1, 2 Allison Sumis,1 Crystal Hervey,1 and Shaguna Mathur1 1 Department of Pediatrics, RUSH University Medical Center, Chicago, IL 60612, USA 2 Departments of Neurology and Biochemistry, RUSH University Medical Center, Chicago, IL 60612, USA Correspondence should be addressed to Elizabeth Berry-Kravis, elizabeth [email protected] Received 12 December 2011; Revised 10 April 2012; Accepted 16 April 2012 Academic Editor: Sheffali Gulati Copyright © 2012 Elizabeth Berry-Kravis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Fragile X syndrome (FXS) is associated with behavior that limits functioning, including distractibility, hyperactivity, impulsivity, hyperarousal, anxiety, mood dysregulation, and aggression. Medication response and side effect data were reviewed retrospectively for 257 patients (age 14 ± 11 years, range 4–60 years, 203 M, 54 F) attending an FXS clinic. Treatment success rates were defined as the percentage of positive response in the form of documented clinical report of improvement in the behavior(s) being targeted over at least a 6-month period on the medication, without side effects requiring medication discontinuance, while failures were defined as discontinuance of medication due to lack of clinical effectiveness or side effects. Success rate for treatment of targeted behaviors with trials of individual medications was 55% for stimulants, 53% for antidepressants, 62% for alpha2-agonists, and 54% for antipsychotics.
    [Show full text]
  • Current P SYCHIATRY
    CP_1006_Erickson.FinalREV3 9/21/06 8:59 AM Page 80 Current p SYCHIATRY Managing maladaptive behaviors in fragile X patients Psychotropics can improve hyperactivity, anxiety, and aggression Craig A. Erickson, MD Fellow, child and adolescent psychiatry ® Dowden Health Media Kimberly A. Stigler, MD Copyright Assistant professor For personalDavid use J. Posey, only MD Associate professor Christopher J. McDougle, MD Albert E. Sterne Professor and chairman Department of psychiatry Indiana University School of Medicine Christian Sarkine Autism Treatment Center James Whitcomb Riley Hospital for Children Indianapolis sychotropics1,2 are used to manage mal- P adaptive and interfering behaviors in 70% of patients with fragile X syndrome (FXS), the leading cause of hereditary mental retardation. Treatment tends to follow a developmental course: • In children, stimulants and alpha-2 agonists are used for attention-deficit/hyperactivity disorder (ADHD)-like symptoms. • In adolescents and adults, selective sero- tonin reuptake inhibitors (SSRIs) are used for anxiety/repetitive phenomena and second-generation antipsychotics (SGAs) for irritability. © images.com / Veer 80 VOL. 5, NO. 10 / OCTOBER 2006 For mass reproduction, content licensing and permissions contact Dowden Health Media. CP_1006_Erickson.FinalREV2 9/20/06 2:44 PM Page 81 Current p SYCHIATRY This course—which is often effective—is Box based primarily on anecdotal descriptions and on Fragile X syndrome’s genetic rationales borrowed from studies of ADHD, and behavioral features obsessive-compulsive disorder (OCD), and autis- tic disorder/related pervasive developmental dis- The term “fragile X” describes how the 3 orders (PDDs). Disease-modifying agents to tar- X chromosome of affected individuals get the underlying brain dysregulation inherent fractures in a folate-deprived medium.
    [Show full text]
  • Tardive Dyskinesia
    TARDIVE SYNDROMES PHENOMENOLOGY, PATHOPHYSIOLOGY, AND MANAGEMENT Cynthia Comella, MD, FAAN, FANA Professor of Neurological Sciences Rush University Medical Center Chicago, IL, USA Science never solves a problem without creating ten more George Bernard Shaw Objectives To describe the history of Tardive Dyskinesia To discuss epidemiology, risk factors and possible pathophysiologic mechanisms of tardive syndromes To demonstrate the varied phenomenology of TD To discuss treatment options for TD DOPAMINE RECEPTOR BLOCKING AGENTS (DRBA) AND TARDIVE DYSKINESIA Described in 1950’s within 5 yrs of development of chlorpromazine for psychosis Initial descriptions were drug induced parkinsonism Subsequently orobuccal-lingual movements persisting beyond medication discontinuation Continuous persistent movements in other regions subsequently described (limbs, face Term “tardive dyskinesia” in 1964 Frei K, Truong D, Fahn S, Jankovic J, Hauser R. J Neurol Sci 2018 Factor et al. Lancet Neurology 2019 DOPAMINE RECEPTOR BLOCKING AGENTS: ASSOCIATED MOVEMENT DISORDERS Acute disorders Acute dystonia Oculogyric crisis Sub-acute disorders Neuroleptic malignant syndrome Akathisia Parkinsonism Tardive disorders Stereotypy Chorea/athetosis Dystonia Akathisia (Tics, myoclonus, tremor) Dystonia Akathisia Neuroleptic Malignant Characteristic Tardive Dyskinesia Acute Tardive Acute Tardive Parkinsonism Syndrome Hours to Weeks to Days to Weeks to Days or weeks to Typical time to onseta Weeks to yearsb Hours to weeks days years months years years
    [Show full text]
  • Fragile X Syndrome
    European Journal of Human Genetics (2008) 16, 666–672 & 2008 Nature Publishing Group All rights reserved 1018-4813/08 $30.00 www.nature.com/ejhg PRACTICAL GENETICS In association with Fragile X syndrome Fragile X syndrome, an X-linked dominant disorder with reduced penetrance, is associated with intellectual and emotional disabilities ranging from learning problems to mental retardation, and mood instability to autism. It is most often caused by the transcriptional silencing of the FMR1 gene, due to an expansion of a CGG repeat found in the 50-untranslated region. The FMR1 gene product, FMRP, is a selective RNA-binding protein that negatively regulates local protein synthesis in neuronal dendrites. In its absence, the transcripts normally regulated by FMRP are over translated. The resulting over abundance of certain proteins results in reduced synaptic strength due to AMPA receptor trafficking abnormalities that lead, at least in part, to the fragile X phenotype. In brief Genetic testing for this repeat expansion is diagnostic for this syndrome, and testing is appropriate in all Fragile X syndrome is a common inherited form of children with developmental delay, mental retardation mental retardation that can be associated with features or autism. of autism. Fragile X syndrome is inherited from individuals, The physical features of fragile X syndrome are subtle usually females, who typically carry an unstable and may not be obvious. premutation allele of the CGG-repeat tract in The vast majority of cases of fragile X syndrome are FMR1. caused by the expansion to over 200 copies of a CGG Premutation carriers are themselves at risk of prema- repeat in the 50-untranslated region of FMR1 that shuts ture ovarian failure and the fragile X-associated tremor/ off transcription of the gene.
    [Show full text]
  • Medical Intervention in Fragile X Syndrome
    MEDICAL INTERVENTION IN FRAGILE X SYNDROME By Randi Hagerman, M.D. The M.I.N.D. Institute University of California, Davis Sacramento, CA 916-734-6348 Children and adults with fragile X syndrome often present to the physician with a variety of behavioral problems. These problems are typically seen in fragile X syndrome so they are presumed to be caused by a lack or a deficiency of normal FMR-1 protein (FMRP) production from the FMR1 gene which is dysfunctional in fragile X syndrome. FMRP is normally present in all neurons and its absence causes some changes in brain structure and function, and presumably changes in neurotransmitter systems that we can improve by the use of medication. Although there is presently no cure for fragile X syndrome, there are a variety of medications that can improve the behavior problems seen in fragile X syndrome. Not every fragile X child will have difficulty with the behaviors discussed below, and not every child will respond to each medication. When problems occur, a medication is usually prescribed on a trial basis and often two or more trials of medication are needed before finding one that works. Sometimes more than one medication is used to treat a combination of problems and sometimes medications are used together because of a synergistic effect. Side effects are discussed below and should be monitored carefully so that they do not become more problematic than the symptom, which is being treated. A close communication and follow up visits are needed with your doctor in order to adjust the medication level and monitor the side effects.
    [Show full text]
  • Movement Disorders Therapeutic Class Review (TCR)
    Movement Disorders Therapeutic Class Review (TCR) April 3, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. Movement
    [Show full text]
  • Persistent Akathisia Associated with Early Tardive Dyskinesia THOMAS R
    Postgrad Med J: first published as 10.1136/pgmj.60.703.359 on 1 May 1984. Downloaded from Postgraduate Medical Journal (May 1984) 60, 359-361 Persistent akathisia associated with early tardive dyskinesia THOMAS R. E. BARNES WALTER M. BRAUDE M.B., B.S., M.R.C.Psych. M.B., Ch.B., D.P.M., M.R.C.Psych. Psychiatric Research Unit, University of Cambridge Clinical School, Addenbrooke's Hospital, Trumpington Street, Cambridge CB2 2QE Summary admitted to hospital in July 1981 and diagnosed as Two psychiatric patients developed moderate or suffering from a schizophrenic illness. This was the severe oro-facial dyskinesia, and limb dyskinesia, at a first occasion that she had been prescribed antipsy- relatively young age and within a year of starting chotic medication, although there was evidence that antipsychotic drug-treatment. This early appearance psychotic symptoms, principally delusions, had been of tardive dyskinesia was preceded by akathisia that present for several years. She was treated initially had developed at the beginning of drug therapy and with oral chlorpromazine to a maximum dose of 500 persisted, despite the reduction of their drug doses to mg per day. Following a test dose of fluphenazine maintenance levels. The possibility that persistent decanoate (Modecate), 12-5 mg i.m., she was started akathisia may herald the early onset of tardive on regular injections of this depot drug, 37.5 mg i.m. dyskinesia, is discussed. every 3 weeks. Within a few days ofthe first injection she complained of an inability to keep her legs still copyright. KEY WORDS: schizophrenia, parkinsonism.
    [Show full text]
  • Tardive Akathisia
    HEALTH & SAFETY: PSYCHIATRIC MEDICATIONS Tardive Akathisia FACT SHEET Tardive Akathisia BQIS Fact Sheets provide a general overview on topics important to supporting an individual’s health and safety and to improving their quality of life. This document provides general information on the topic and is not intended to replace team assessment, decision-making, or medical advice. This is the ninth of ten Fact Sheets regarding psychotropic medications. Intended Outcomes Individuals will understand the symptoms, common causes, and treatment of tardive akathisia. Definitions Akathisia: A movement disorder characterized by motor restlessness/a feeling of inner restlessness with a compelling need to be moving. Tardive akathisia: A severe prolonged form of akathisia which may persist after stopping the medica- tion causing the symptoms. Facts • Akathisia is: – the most common drug induced movement disorder. – a side effect of medication. – most often caused by antipsychotic medications that block dopamine. • Medications with akathisia as a potential side effect include: – Benzisothiazole (ziprasidone) – Benzisoxazole (iloperidone) – Butyrophenones (haloperidol, droperidol) – Calcium channel blockers (flunarizine, cinnarizine) – Dibenzazepine (loxapine, asenapine) – Dibenzodiazepine (clozapine, quetiapine) – Diphenylbutylpiperidine (pimozide) – Indolones (molindone) – Lithium – Phenothiazines (chlorpromazine, triflupromazine, thioridazine, mesoridazine, trifluoperazine, prochlorperazine, perphenazine, fluphenazine, perazine) Bureau of Quality Improvement
    [Show full text]
  • What Is Tardive Dyskinesia?
    What is Tardive Dyskinesia? 1919 University Avenue West, Suite 400, St. Paul, MN 55114 | Tel. 651-645-2948 or 888-NAMIHELPS | www.namihelps.org What is Tardive Dyskinesia? Tardive Dyskinesia (TD) is a side effect of taking antipsychotic medication. It’s a movement disorder that can appear months, years, even decades after starting to take antipsychotic medication. It’s estimated that 20-50% of people with depression, schizophrenia, bipolar disorder or schizoaffective disorder taking antipsychotics, particularly first generation, will develop TD. What are the symptoms? Signs and symptoms include: • repetitive jerking movements of the arms or legs • trunk and hip rocking, jerking or thrusting • rapid eye blinking • Tongue rolling, or darting in or out of the mouth • lip smacking. pursing or puckering, • jaw clenching or grimacing • twisting or rhythmic movement in the fingers or toes Who is at risk? We know that taking older “first generation” antipsychotics places someone at greater risk. Other risk factors include: • being a woman • being over age 55 • having diabetes • having a substance use disorder (including alcoholism) How can it be prevented? While TD can’t be prevented, it’s important to identify it early. It’s recommended that people be screened every six months or at least every year using what’s called “The Abnormal Involuntary Movement Scale”. Be sure to note which symptoms you are experiencing, when the symptoms began to appear, how frequent they are, and how they impact your daily routine. What are the treatments? If you or a loved one begins showing symptoms talk to your doctor right away – but do not abruptly stop taking the antipsychotic.
    [Show full text]